Top Markets
Coin of the day
CARsgen Therapeutics Holdings Limited CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited

2171
Classificação em ações #9600
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in... CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Preço da ação
$1.72
Última sincronização: 2026-08-28
Valor de mercado
$981.92M
Variação (1 dia)
-1.68%
Variação (1 ano)
-41.83%
País
CN
Negociar CARsgen Therapeutics Holdings Limited (2171)

Categoria

Receita da CARsgen Therapeutics Holdings Limited (2171)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da CARsgen Therapeutics Holdings Limited, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da CARsgen Therapeutics Holdings Limited de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH